The Defense Industrial Base Consortium aims to diversify and expand a robust and resilient defense industrial base to meet national security needs.

The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) supports the Biomedical Advanced Research and Development Authority (BARDA) and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of required raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services.

The Rapid Response Partnership Vehicle (RRPV) supports the Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure (MCM) product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.

MCDC develops prototypes to prevent, diagnose and treat illnesses caused by chemical, biological, radiological, and nuclear agents.

CWMD engages industry and academia to develop and prototype mature technologies to counter weapons of mass destruction.